MX2022015866A - Metil 2-(fluorometil)-5-oxo-4-fenil-4,5,6,7-tetrahidro-1h- ciclopenta[b]piridin-3-carboxilatos y metil 2-(fluorometil)-5-oxo- 4-fenil- 1,4,5,7-tetrahidrofuro[3,4-b]piridin-3-carboxilatos como activadores de cav1.2. - Google Patents

Metil 2-(fluorometil)-5-oxo-4-fenil-4,5,6,7-tetrahidro-1h- ciclopenta[b]piridin-3-carboxilatos y metil 2-(fluorometil)-5-oxo- 4-fenil- 1,4,5,7-tetrahidrofuro[3,4-b]piridin-3-carboxilatos como activadores de cav1.2.

Info

Publication number
MX2022015866A
MX2022015866A MX2022015866A MX2022015866A MX2022015866A MX 2022015866 A MX2022015866 A MX 2022015866A MX 2022015866 A MX2022015866 A MX 2022015866A MX 2022015866 A MX2022015866 A MX 2022015866A MX 2022015866 A MX2022015866 A MX 2022015866A
Authority
MX
Mexico
Prior art keywords
fluoromethyl
carboxylates
pyridine
phenyl
methyl
Prior art date
Application number
MX2022015866A
Other languages
English (en)
Inventor
James Neef
Zaixing Li
Sung David C Kim
Chui Lu
Danuta Lubicka
Hye - Yeon PARK
Tejaskumar Pankajbhai Pathak
Amir Masoud Sadaghiani
Xilin Zhou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022015866A publication Critical patent/MX2022015866A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación proporciona un compuesto de acuerdo con la fórmula (I) (ver Fórmula) (I) o una sal farmacéuticamente aceptable de este como activadores de CaV1.22 para el tratamiento de esquizofrenia, trastorno bipolar, trastorno depresivo mayor, trastorno debido al uso de sustancias, TDAH, síndrome de Phelan-McDermid, trastornos del espectro autista, esclerosis múltiple, demencia frontotemporal, enfermedad de Alzheimer, síndrome de Brugada, síndrome de QT corto, o síndrome de repolarización precoz.
MX2022015866A 2020-06-15 2021-06-11 Metil 2-(fluorometil)-5-oxo-4-fenil-4,5,6,7-tetrahidro-1h- ciclopenta[b]piridin-3-carboxilatos y metil 2-(fluorometil)-5-oxo- 4-fenil- 1,4,5,7-tetrahidrofuro[3,4-b]piridin-3-carboxilatos como activadores de cav1.2. MX2022015866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/096177 WO2021253180A1 (en) 2020-06-15 2020-06-15 Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
PCT/IB2021/055183 WO2021255607A1 (en) 2020-06-15 2021-06-11 Methyl 2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1h-cyclopenta[b]pyridine-3-carboxylates and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylates as cav1.2 activators

Publications (1)

Publication Number Publication Date
MX2022015866A true MX2022015866A (es) 2023-01-24

Family

ID=76523252

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015866A MX2022015866A (es) 2020-06-15 2021-06-11 Metil 2-(fluorometil)-5-oxo-4-fenil-4,5,6,7-tetrahidro-1h- ciclopenta[b]piridin-3-carboxilatos y metil 2-(fluorometil)-5-oxo- 4-fenil- 1,4,5,7-tetrahidrofuro[3,4-b]piridin-3-carboxilatos como activadores de cav1.2.

Country Status (20)

Country Link
US (1) US11919911B2 (es)
EP (1) EP4165047A1 (es)
JP (1) JP2023530917A (es)
KR (1) KR20230022982A (es)
CN (1) CN115836076A (es)
AR (1) AR122615A1 (es)
AU (1) AU2021293976B2 (es)
BR (1) BR112022025212A2 (es)
CA (1) CA3182354A1 (es)
CL (1) CL2022003525A1 (es)
CO (1) CO2022017502A2 (es)
CR (1) CR20230008A (es)
DO (1) DOP2022000276A (es)
EC (1) ECSP23001748A (es)
IL (1) IL298448A (es)
MX (1) MX2022015866A (es)
PE (1) PE20231079A1 (es)
TW (1) TW202214651A (es)
UY (1) UY39265A (es)
WO (2) WO2021253180A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004596B2 (en) 2014-07-31 2018-06-26 Lensgen, Inc. Accommodating intraocular lens device
WO2023111799A1 (en) * 2021-12-13 2023-06-22 Novartis Ag PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CaV1.2 ACTIVATORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201395A (en) 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
EP0111455A3 (de) 1982-12-10 1984-07-25 Ciba-Geigy Ag Ungesättigte Lactone
DE3410645A1 (de) 1984-03-23 1985-09-26 Bayer Ag, 5090 Leverkusen L-alkylsubstituierte 1,4-dihydropyridinlactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US4567268A (en) 1984-04-03 1986-01-28 Merck & Co., Inc. Process for preparation of certain tetrahydrofuro[3,4-b]pyridines
US6518279B2 (en) * 1999-03-04 2003-02-11 Abbott Laboratories Cyclopentanone dihydropyridine compounds useful as potassium channel openers
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2010015037A1 (en) 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions

Also Published As

Publication number Publication date
AU2021293976A1 (en) 2022-11-24
ECSP23001748A (es) 2023-03-31
WO2021253180A1 (en) 2021-12-23
AU2021293976B2 (en) 2023-12-14
KR20230022982A (ko) 2023-02-16
BR112022025212A2 (pt) 2023-01-03
CN115836076A (zh) 2023-03-21
JP2023530917A (ja) 2023-07-20
US11919911B2 (en) 2024-03-05
DOP2022000276A (es) 2023-01-15
CO2022017502A2 (es) 2022-12-20
US20210395261A1 (en) 2021-12-23
IL298448A (en) 2023-01-01
EP4165047A1 (en) 2023-04-19
CA3182354A1 (en) 2021-12-23
PE20231079A1 (es) 2023-07-17
WO2021255607A1 (en) 2021-12-23
CL2022003525A1 (es) 2023-08-11
UY39265A (es) 2022-01-31
AR122615A1 (es) 2022-09-21
TW202214651A (zh) 2022-04-16
CR20230008A (es) 2023-01-25

Similar Documents

Publication Publication Date Title
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
MX2022015866A (es) Metil 2-(fluorometil)-5-oxo-4-fenil-4,5,6,7-tetrahidro-1h- ciclopenta[b]piridin-3-carboxilatos y metil 2-(fluorometil)-5-oxo- 4-fenil- 1,4,5,7-tetrahidrofuro[3,4-b]piridin-3-carboxilatos como activadores de cav1.2.
PH12019500712A1 (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
TW200608969A (en) Heterocyclic boronic acid compounds
DE602004021959D1 (de) Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
CR20210626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
SE9904508D0 (sv) New compounds
NZ629453A (en) Thiazole derivatives as alpha 7 nachr modulators
MX2009010296A (es) Derivado de anillo fusionado nitrogenado, composicion farmaceutica que lo contiene, y uso del mismo para propositos medicos.
TW200740806A (en) Bridged N-cyclic sulfonamido inhibitors of gamma secretase
JP2009533343A (ja) ヒスタミンｈ４受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール
JP2000500489A (ja) 三環置換基を有するオキサゾリジノン抗菌剤
DE60209362D1 (de) 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten
MX2019008116A (es) Proceso para la preparacion de compuestos de 5-amino-6h-tiazolo[4, 5-d]pirimidina-2,7-diona 3-sustituidos.
PE20121507A1 (es) Derivados de (heterociclo-piperidina condensada)-(piperazinil)-1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1-alcanona como inhibidores de p75
ZA202200660B (en) Process for the preparation of ridinilazole and crystalline forms thereof
MXPA04000779A (es) 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades.
JP6207625B2 (ja) チロシンキナーゼ阻害剤としてのインドリノン誘導体
AR039475A1 (es) 6-alquiliden-penems triciclicos como inhibidores de beta-lactamasa
ATE432262T1 (de) Pyrazolphenylderivate als ppar-aktivatoren